- Roche's navify Digital Pathology software platform now
offers Ibex's Artificial Intelligence (AI) algorithms to support
clinicians in the diagnosis of breast and prostate cancer.
- Roche and Ibex cloud-based digital pathology and AI
solutions run on Amazon Web Services (AWS), enabling a scalable and
sustainable ecosystem for pathology laboratories.
- This collaboration builds on Roche's Digital Pathology Open
Environment on the navify platform, expanding the company's
commitment to improving patient care and advancing personalised
healthcare through innovation.
TUCSON, Ariz., Oct. 26, 2023 /PRNewswire/ -- Roche (SIX: RO,
ROG; OTCQX: RHHBY) announced today collaborations with Ibex Medical
Analytics and Amazon Web Services, enabling pathology laboratories
to access Ibex's AI-powered decision support tools to support
clinicians in breast and prostate cancer diagnosis through the
navify® Digital Pathology software platform.
Digital pathology refers to the digitalisation of the
traditional pathology workflow starting from slide scanning to
visualisation to analysis. Digital pathology is transforming
traditional histopathology by improving efficiency, depth of
analysis, and providing an opportunity for collaboration in
pathology workflows. The integrated artificial intelligence
(AI)-based tools can be applied to help enhance clinical decision
support, improve productivity and shorten turnaround time in
pathology laboratories.
"This exciting collaboration brings powerful AI solutions to
pathology labs," said Michael
Rivers, Lifecycle Leader for Roche Digital Pathology. "Using
the navify Digital Pathology platform pathologists can securely
access third-party AI-powered technology alongside Roche's growing
menu of AI-based image analysis tools in an efficient clinical
workflow."
Ibex's AI algorithms help clinicians in the diagnosis of breast
and prostate biopsies and provide efficient, accurate and timely
cancer diagnosis, support case prioritisation, determine the cancer
grading and subtype, and identify important non-cancerous features.
All of this detailed diagnosis information is displayed seamlessly
in the navify Digital Pathology solution.
The Ibex algorithms are used at laboratories and hospitals
worldwide, and help clinicians improve patient care as demonstrated
by multiple clinical studies performed in the United States and Europe1,2,3,4. These algorithms are
currently for Research Use Only, not for use in diagnostic
procedures, in the United States,
and CE-Marked for IVD use in Europe for breast and prostate cancer
detection in multiple workflows.
"Our collaboration with Roche is driving new AI-powered
workflows that help pathologists and laboratories realise the full
potential of going digital," said Joseph
Mossel, CEO and Co-founder of Ibex Medical Analytics. "The
next phase in the evolution of digital pathology is open platforms
that enable technology providers to join forces and offer
integrated software solutions that improve lab efficiency, biopsy
review and ultimately the quality of patient care."
Roche's solution and Ibex's algorithms operate on the highly
secure and scalable Amazon Web Services. This cloud infrastructure
provides customers with flexibility, security, computing capacity,
responsiveness and confidence to accelerate the adoption of digital
pathology and AI.
As cancer incidence and pathology workloads continue to increase
globally, cloud-based services enable laboratories and health
systems to safely, reliably and cost-effectively scale up the
volume of slide images they analyse, roll out new applications, add
new digitised sites to their network, and expand to new
geographies.
About Roche Digital Pathology
As the leading
provider of pathology lab solutions, Roche is delivering an
end-to-end digital pathology solution from tissue staining to
producing high-quality digital images that can be reliably assessed
using automated AI-based clinical image analysis algorithms. We
minimise variables that can impact analysis, and it is this
end-to-end development that produces the quality results healthcare
providers and researchers can depend on. With the acceleration of
immunotherapy and the development of more complex assays, Roche is
moving these traditionally research-oriented tools into routine
clinical practice and is committed to investing in and shaping the
future of pathology.
About Roche
Founded in 1896 in Basel,
Switzerland, as one of the first industrial manufacturers of
branded medicines, Roche has grown into the world's largest
biotechnology company and the global leader in in-vitro
diagnostics. The company pursues scientific excellence to discover
and develop medicines and diagnostics for improving and saving the
lives of people around the world. We are a pioneer in personalised
healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care
for each person we partner with many stakeholders and combine our
strengths in Diagnostics and Pharma with data insights from the
clinical practice.
In recognising our endeavour to pursue a long-term perspective
in all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the thirteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United
States, is a wholly owned member of the Roche Group. Roche
is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
In the United States, the Ibex
algorithms are for Research use Only, not for diagnostic
procedures.
All trademarks used or mentioned in this release are protected
by law.
References
[1] Pantanowitz et al., An artificial intelligence algorithm
for prostate cancer diagnosis in whole slide images of core needle
biopsies: a blinded clinical validation and deployment study, THE
LANCET Digital Health Aug 2020
[2] Sandbank et al., Validation and real-world clinical
application of an artificial intelligence algorithm for breast
cancer detection in biopsies; npj Breast Cancer 8, 129 (2022)
[3] Comperat et al., Clinical Level AI-Based Solution for
Primary Diagnosis and Reporting of Prostate Biopsies in Routine
Use: A Prospective Reader Study, European Congress of Pathology
2021
[4] Raoux et al., Novel AI-Based Solution for Supporting
Primary Diagnosis of Prostate Cancer Increases the Accuracy and
Efficiency of Reporting in Clinical Routine, USCAP 2021
Roche Media Relations
Jo Lynn
Garing, +1 317-363-7286
View original
content:https://www.prnewswire.co.uk/news-releases/roche-collaborates-with-ibex-and-amazon-web-services-to-accelerate-adoption-of-ai-enabled-digital-pathology-solutions-to-help-improve-cancer-diagnoses-301967948.html